ASP Isotopes Inc. has announced a significant supply agreement with Isotopia Molecular Imaging Ltd. to provide enriched Gadolinium-160 (Gd-160), a crucial precursor for producing Terbium-161 (Tb-161). The four-year contract, starting in 2026, is valued at a minimum of $1 million annually. This partnership aims to address longstanding supply challenges for Gd-160, facilitating the advancement of Tb-161-based therapies for cancers such as prostate cancer and neuroendocrine tumors. ASP Isotopes will utilize its Quantum Enrichment technology to ensure a stable supply of Gd-160, supporting Isotopia's efforts to scale production and advance Tb-161-labeled drug candidates toward commercialization. This collaboration is expected to accelerate the clinical adoption of Tb-161, potentially redefining cancer treatment paradigms.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。